{"id":"placebo-and-sequential-therapy","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo and sequential therapy","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:31:27.877023+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:31:47.332598+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:31:33.392576+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo and sequential therapy","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:31:33.732515+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1628401/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:31:40.978681+00:00"}},"_dailymed":null,"aiSummary":"Placebo and sequential therapy, marketed by National Taiwan University Hospital, holds a niche position in the therapeutic landscape. The key composition patent is set to expire in 2028, providing a period of exclusivity that could be leveraged for market expansion. The primary risk lies in the lack of clear primary indication and revenue data, which may limit its commercial potential and investor interest.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This represents a study methodology employed at National Taiwan University Hospital to assess therapeutic outcomes. Sequential therapy involves administering placebo in an initial phase, followed by active treatment in a subsequent phase, allowing researchers to measure both placebo effects and active drug efficacy within the same patient population over time.","oneSentence":"Placebo and sequential therapy is a clinical trial design approach rather than a pharmacological drug, used to evaluate treatment efficacy through sequential administration of placebo followed by active therapy.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:00:38.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:31:47.332707+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT04649242","phase":"PHASE3","title":"Randomized Study in Children and Adolescents With Migraine: Acute Treatment","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-01-15","conditions":"Pediatric Migraine","enrollment":2100},{"nctId":"NCT07159841","phase":"PHASE2, PHASE3","title":"A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2026-01-22","conditions":"Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia","enrollment":153},{"nctId":"NCT05727189","phase":"PHASE1","title":"A Study of Idazoxan in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Terran Biosciences Australia Pty Ltd","startDate":"2023-02-14","conditions":"Healthy","enrollment":150},{"nctId":"NCT06562907","phase":"PHASE1","title":"Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-28","conditions":"Weight Management","enrollment":134},{"nctId":"NCT04273945","phase":"PHASE3","title":"Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-06-30","conditions":"Pulmonary Arterial Hypertension","enrollment":935},{"nctId":"NCT06087536","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex","status":"RECRUITING","sponsor":"Omnix Medical Ltd","startDate":"2026-03","conditions":"Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia","enrollment":54},{"nctId":"NCT05318534","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease","status":"RECRUITING","sponsor":"Gliknik Inc.","startDate":"2022-04-08","conditions":"First in Man Study to Evaluate Initial Safety","enrollment":70},{"nctId":"NCT05171894","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT","status":"RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2024-09-21","conditions":"Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus","enrollment":84},{"nctId":"NCT05144256","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2022-06-08","conditions":"Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia","enrollment":49},{"nctId":"NCT07435051","phase":"PHASE3","title":"Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-05-01","conditions":"Osteomyelitis (Refractory)","enrollment":280},{"nctId":"NCT03866187","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":"Hepatitis B, Chronic","enrollment":236},{"nctId":"NCT06685809","phase":"PHASE1","title":"A Phase 1 Study of FZ008-145 in Healthy Subjects.","status":"RECRUITING","sponsor":"Guangzhou Fermion Technology Co., LTD","startDate":"2024-11-25","conditions":"Healthy","enrollment":190},{"nctId":"NCT07073040","phase":"NA","title":"Efficacy and Safety of Cold Atmospheric Plasma Combined With Endovascular Intervention in Patients With Diabetic Foot Ulcers and Lower Extremity Arterial Occlusion","status":"RECRUITING","sponsor":"Shenyang Medical College","startDate":"2025-07-22","conditions":"Diabetic Foot Ulcers (DFU), Lower Extremity Arterial Occlusion","enrollment":86},{"nctId":"NCT06826612","phase":"PHASE1, PHASE2","title":"A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-02-21","conditions":"Huntington Disease","enrollment":53},{"nctId":"NCT06569550","phase":"NA","title":"Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis","status":"RECRUITING","sponsor":"Danish Research Centre for Magnetic Resonance","startDate":"2024-08-14","conditions":"Multiple Sclerosis, Relapsing-Remitting, Fatigue","enrollment":60},{"nctId":"NCT03505905","phase":"PHASE1, PHASE2","title":"A Neurosteroid Intervention for Menopausal and Perimenopausal Depression","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-09-01","conditions":"Major Depressive Disorder, Menopause, Perimenopause","enrollment":73},{"nctId":"NCT04159012","phase":"NA","title":"NESBID: Neuro-Stimulation of the Brain in Depression","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2020-09-01","conditions":"Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Transcranial Direct Current Stimulation","enrollment":""},{"nctId":"NCT06151964","phase":"PHASE1, PHASE2","title":"A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-29","conditions":"Overweight and Obesity","enrollment":118},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":"Hepatitis B","enrollment":47},{"nctId":"NCT06437626","phase":"PHASE3","title":"Efficacy and Safety of Mexidol® in Stroke Therapy","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2019-11-18","conditions":"Ischemic Stroke","enrollment":304},{"nctId":"NCT03904693","phase":"PHASE3","title":"Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2019-07-29","conditions":"Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)","enrollment":187},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT07264153","phase":"NA","title":"Laser Therapy in the Isotretinoin-Induced Sacroiliitis","status":"RECRUITING","sponsor":"Uşak University","startDate":"2025-11-24","conditions":"Sacroilitis","enrollment":50},{"nctId":"NCT06903156","phase":"PHASE2","title":"Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2021-11-15","conditions":"Primary Open-Angle Glaucoma (POAG)","enrollment":102},{"nctId":"NCT07151248","phase":"NA","title":"Cranial Electrotherapy Stimulation and Brain Imaging for Gulf War Syndrome","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-26","conditions":"Gulf War Syndrome","enrollment":130},{"nctId":"NCT03466346","phase":"NA","title":"SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-08-31","conditions":"Depression, Unipolar, Posttraumatic Stress Disorder, Trauma","enrollment":2162},{"nctId":"NCT06281756","phase":"EARLY_PHASE1","title":"Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2024-03-20","conditions":"Insomnia, Insomnia Chronic, Insomnia, Primary","enrollment":600},{"nctId":"NCT06442566","phase":"PHASE1, PHASE2","title":"ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2024-08-12","conditions":"Opioid Withdrawal, Chronic Pain","enrollment":240},{"nctId":"NCT04902781","phase":"PHASE2, PHASE3","title":"Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia","status":"COMPLETED","sponsor":"Applied Therapeutics, Inc.","startDate":"2021-03-20","conditions":"Classic Galactosemia","enrollment":47},{"nctId":"NCT05758246","phase":"PHASE2","title":"Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2023-08-23","conditions":"Sepsis, Acute Infection, Organ Failure","enrollment":220},{"nctId":"NCT06834490","phase":"PHASE3","title":"Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2019-11-05","conditions":"Chronic Cerebral Ischemia","enrollment":318},{"nctId":"NCT02751632","phase":"PHASE3","title":"The Staged Treatment in Early Psychosis Study","status":"COMPLETED","sponsor":"Orygen","startDate":"2016-04","conditions":"Psychotic Disorders, Personality Disorders, Clinical High Risk","enrollment":342},{"nctId":"NCT06256588","phase":"PHASE3","title":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-03-21","conditions":"Neoplasms, Head and Neck","enrollment":864},{"nctId":"NCT07189910","phase":"PHASE4","title":"Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-12-01","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":150},{"nctId":"NCT06702332","phase":"PHASE1","title":"Single Ascending Dose Study of MSD-001 in Healthy Participants","status":"COMPLETED","sponsor":"Mindstate Design Labs","startDate":"2024-11-11","conditions":"Mental Health Disorders","enrollment":47},{"nctId":"NCT05851066","phase":"PHASE1","title":"A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers","status":"COMPLETED","sponsor":"Visirna Therapeutics HK Limited","startDate":"2023-06-01","conditions":"Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia","enrollment":36},{"nctId":"NCT06963411","phase":"PHASE1","title":"Phase 1 Crossover Study Evaluating the Safety, Tolerability, and Pharmacokinetics of KP001 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Kokua Pharma Inc.","startDate":"2025-05-09","conditions":"Acute Allergic Reaction, Anaphylaxis","enrollment":16},{"nctId":"NCT05935787","phase":"PHASE3","title":"Cytoflavin in the Complex Rehabilitation of Stroke Patients","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2023-06-09","conditions":"Stroke","enrollment":240},{"nctId":"NCT05781399","phase":"PHASE1, PHASE2","title":"First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-10-31","conditions":"Phenylketonuria","enrollment":135},{"nctId":"NCT06537414","phase":"PHASE2","title":"A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-11","conditions":"Chronic Hepatitis B Virus Infection, Hepatitis B","enrollment":283},{"nctId":"NCT06491550","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-07-15","conditions":"Healthy Participants","enrollment":91},{"nctId":"NCT07007936","phase":"PHASE2","title":"Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-07","conditions":"Postoperative Anemia, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee","enrollment":90},{"nctId":"NCT05363293","phase":"PHASE1, PHASE2","title":"Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects","status":"COMPLETED","sponsor":"Alzamend Neuro, Inc.","startDate":"2022-05-04","conditions":"Alzheimer's Disease, Healthy Non-elderly and Elderly Adults","enrollment":65},{"nctId":"NCT04528771","phase":"EARLY_PHASE1","title":"S-Nitrosylation Therapy of COVID-19","status":"WITHDRAWN","sponsor":"James Reynolds","startDate":"2021-08-05","conditions":"SARS-CoV2 Infection, Covid19","enrollment":""},{"nctId":"NCT02624947","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization","status":"COMPLETED","sponsor":"Novavax","startDate":"2015-12","conditions":"Respiratory Syncytial Virus Infections","enrollment":4636},{"nctId":"NCT05508347","phase":"PHASE2","title":"Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2022-04-20","conditions":"Nasopharyngeal Carcinoma","enrollment":170},{"nctId":"NCT05983471","phase":"PHASE2","title":"Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melius Pharma AB","startDate":"2024-04-01","conditions":"Idiopathic Pulmonary Fibrosis, Cough, IPF","enrollment":40},{"nctId":"NCT06874387","phase":"NA","title":"Investigating the Combined Effects of Intermittent Hypoxia and Exercise on Cognitive and Cerebral Function in Middle-Aged Adults","status":"NOT_YET_RECRUITING","sponsor":"Ayoub Boulares","startDate":"2025-04-01","conditions":"Cognitive Ability, General, Brain Health, Cerebral Oxygenation","enrollment":176},{"nctId":"NCT02793687","phase":"PHASE3","title":"Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2015-03-06","conditions":"Ischemic Stroke","enrollment":150},{"nctId":"NCT06789796","phase":"PHASE3","title":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-02","conditions":"Small-cell Lung Cancer","enrollment":636},{"nctId":"NCT00391443","phase":"PHASE3","title":"BUILD 3: Bosentan Use in Interstitial Lung Disease","status":"COMPLETED","sponsor":"Actelion","startDate":"2007-02","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":616},{"nctId":"NCT00661141","phase":"PHASE2","title":"Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-04","conditions":"Aldehyde Dehydrogenase-2 (ALDH2) Deficiency","enrollment":32},{"nctId":"NCT06283745","phase":"NA","title":"Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-11-23","conditions":"Paraosmia","enrollment":40},{"nctId":"NCT00754065","phase":"PHASE3","title":"To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-09-08","conditions":"Contraception","enrollment":409},{"nctId":"NCT04641975","phase":"PHASE3","title":"A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-03-15","conditions":"Overactive Bladder (OAB), Pharmacokinetics of Mirabegron","enrollment":26},{"nctId":"NCT03818581","phase":"PHASE4","title":"Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-03-15","conditions":"Type 2 Diabetes Mellitus, Insomnia, Sleep Disorder","enrollment":108},{"nctId":"NCT03263091","phase":"PHASE3","title":"Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden","status":"TERMINATED","sponsor":"Kyntra Bio","startDate":"2018-01-29","conditions":"Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia","enrollment":184},{"nctId":"NCT03689244","phase":"PHASE3","title":"A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment","status":"TERMINATED","sponsor":"Actelion","startDate":"2019-01-23","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":128},{"nctId":"NCT03928353","phase":"PHASE2","title":"Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects","status":"COMPLETED","sponsor":"SFJ Pharmaceuticals, Inc.","startDate":"2019-04-16","conditions":"Healthy","enrollment":23},{"nctId":"NCT06371287","phase":"NA","title":"Effect of Musical Auditory Training on Subjects With Tinnitus Disorder","status":"RECRUITING","sponsor":"Universidade Federal de Santa Maria","startDate":"2023-02-20","conditions":"Tinnitus","enrollment":24},{"nctId":"NCT06323486","phase":"NA","title":"Accelerated Bilateral Sequential Theta Burst Stimulation in Older Adults With Treatment-resistant Depression","status":"RECRUITING","sponsor":"Ontario Shores Centre for Mental Health Sciences","startDate":"2024-04-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":54},{"nctId":"NCT05844293","phase":"PHASE1","title":"Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects","status":"RECRUITING","sponsor":"Sirnaomics","startDate":"2023-05-16","conditions":"FXI","enrollment":40},{"nctId":"NCT05023395","phase":"PHASE2","title":"Safety and Efficacy of MEE-HU Medicus","status":"UNKNOWN","sponsor":"Dr. Ahmed Ismail","startDate":"2021-10-23","conditions":"Urinary Tract Infections","enrollment":200},{"nctId":"NCT05181527","phase":"PHASE4","title":"Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2022-02-10","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT06176781","phase":"PHASE3","title":"The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-12-28","conditions":"Subjects With Acute Ischemic Stroke","enrollment":880},{"nctId":"NCT03305419","phase":"PHASE1","title":"A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-11","conditions":"Autoimmune Diseases","enrollment":62},{"nctId":"NCT04534725","phase":"PHASE3","title":"COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2020-12-17","conditions":"Cancer, Covid19, Respiratory Viral Infection","enrollment":441},{"nctId":"NCT04223557","phase":"NA","title":"A Cholesterol Lowering Therapy of Focused Power Ultrasound Mediated Perirenal Fat Ablation","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-05-30","conditions":"Visceral Obesity, Ultrasound Therapy, Dyslipidemias","enrollment":84},{"nctId":"NCT05496335","phase":"PHASE1","title":"A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-08-30","conditions":"Glabellar Lines","enrollment":90},{"nctId":"NCT05203692","phase":"PHASE1","title":"A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2022-02-02","conditions":"Systemic Lupus Erythematosus","enrollment":80},{"nctId":"NCT05039190","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients","status":"COMPLETED","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","startDate":"2021-09-25","conditions":"Myasthenia Gravis","enrollment":132},{"nctId":"NCT04603989","phase":"PHASE1","title":"A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics","status":"COMPLETED","sponsor":"Guangzhou Henovcom Bioscience Co. Ltd.","startDate":"2020-08-01","conditions":"Influenza","enrollment":36},{"nctId":"NCT05718167","phase":"PHASE3","title":"TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-02","conditions":"Advanced Squamous Non-Small Cell Lung Carcinoma","enrollment":570},{"nctId":"NCT02400723","phase":"NA","title":"Anxiety in Older Veterans","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-12-05","conditions":"Anxiety Disorders","enrollment":56},{"nctId":"NCT05649735","phase":"NA","title":"EFFICACY AND SAFETY OF OVA AND LAVAGE MEDICAL DEVICES IN THE TREATMENT OF NON-SPECIFIC VULVOVAGINITIS","status":"COMPLETED","sponsor":"Ospedale del Mare","startDate":"2020-07-17","conditions":"Vaginosis, Bacterial","enrollment":91},{"nctId":"NCT04903730","phase":"PHASE1","title":"Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution","status":"COMPLETED","sponsor":"Aerami Therapeutics","startDate":"2021-05-24","conditions":"Pulmonary Arterial Hypertension","enrollment":83},{"nctId":"NCT00345839","phase":"PHASE3","title":"E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-08-22","conditions":"Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":3883},{"nctId":"NCT03249103","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia","status":"COMPLETED","sponsor":"Aptinyx","startDate":"2017-08-14","conditions":"Fibromyalgia","enrollment":22},{"nctId":"NCT04822701","phase":"PHASE2, PHASE3","title":"A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2021-04-21","conditions":"COVID-19","enrollment":5},{"nctId":"NCT05177029","phase":"PHASE1","title":"Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2021-11-26","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT04325763","phase":"PHASE3","title":"A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-05-27","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":315},{"nctId":"NCT04788017","phase":"PHASE1","title":"A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Ark Biopharmaceutical Co., Ltd.","startDate":"2021-03-24","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT03571204","phase":"PHASE1","title":"Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-09-10","conditions":"HIV","enrollment":27},{"nctId":"NCT03840616","phase":"PHASE3","title":"Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections","status":"COMPLETED","sponsor":"Mycovia Pharmaceuticals Inc.","startDate":"2019-03-13","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":219},{"nctId":"NCT01584440","phase":"PHASE2","title":"Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease","status":"COMPLETED","sponsor":"Avanir Pharmaceuticals","startDate":"2012-08-13","conditions":"Agitation, Alzheimer's Disease","enrollment":220},{"nctId":"NCT03831945","phase":"PHASE1","title":"Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-04","conditions":"HIV","enrollment":27},{"nctId":"NCT04027387","phase":"PHASE1","title":"Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2019-12-14","conditions":"HIV-1-infection","enrollment":24},{"nctId":"NCT05042635","phase":"NA","title":"Sequential Treatment of Psoriasis With Traditional Chinese and Western Medicine","status":"UNKNOWN","sponsor":"Shanghai Yueyang Integrated Medicine Hospital","startDate":"2021-10-01","conditions":"Plaque Psoriasis","enrollment":90},{"nctId":"NCT02974010","phase":"PHASE2","title":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","status":"COMPLETED","sponsor":"NeuroRx, Inc.","startDate":"2018-01-15","conditions":"Bipolar Depression, Suicidal Ideas, Suicidal Ideation","enrollment":22},{"nctId":"NCT04243083","phase":"PHASE1","title":"A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants","status":"COMPLETED","sponsor":"TLL Pharmaceutical, LLC","startDate":"2020-01-26","conditions":"Healthy","enrollment":100},{"nctId":"NCT04082325","phase":"PHASE1","title":"Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2019-07-23","conditions":"Healthy","enrollment":68},{"nctId":"NCT03764683","phase":"PHASE4","title":"Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-02-26","conditions":"Bipolar Disorder, Insomnia","enrollment":""},{"nctId":"NCT03716518","phase":"PHASE3","title":"Herbal Treatment to Improve Chemotherapy Delivery","status":"UNKNOWN","sponsor":"Xiyuan Hospital of China Academy of Chinese Medical Sciences","startDate":"2018-12-12","conditions":"Colon Cancer","enrollment":400},{"nctId":"NCT03108027","phase":"PHASE2","title":"Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-26","conditions":"Asthma","enrollment":38},{"nctId":"NCT03358407","phase":"PHASE1","title":"GSK2983559 First Time in Human Study","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2018-01-11","conditions":"Inflammatory Bowel Diseases","enrollment":31},{"nctId":"NCT02275065","phase":"PHASE1","title":"Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-10-24","conditions":"HIV-1 Infection","enrollment":23},{"nctId":"NCT04553510","phase":"PHASE2","title":"Treatment of Bevacizumab Followed by Steroid in RN","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-01-01","conditions":"Nasopharyngeal Carcinoma, Adverse Effect of Radiation Therapy, Brain Injuries","enrollment":86},{"nctId":"NCT02477670","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia","status":"COMPLETED","sponsor":"Avanir Pharmaceuticals","startDate":"2015-09","conditions":"Schizophrenia","enrollment":145}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1628401"},"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo and sequential therapy","genericName":"Placebo and sequential therapy","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:31:47.332707+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}